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Background: Decline in platelet count (DPC) is associated with poor prognosis in patients undergoing coronary intervention. The purpose of this 
study was to assess the incidence and impact of DPC in patients undergoing transcatheter aortic valve replacement (TAVR).
methods: Data from 495 consecutive pts undergoing TAVR were pooled from 2 medical centers. The % DPC after the procedure was calculated as 
100*(baseline platelet count - nadir platelet count) / baseline platelet count. Patients were divided in 3 groups according to the % of DPC: no/mild 
50%. VARC outcomes were reported at 30 days and 1 year.
results: Among the total cohort, 106 patients had baseline thrombocytopenia (21.4%, platelet <150/microliter) vs. 396 patients after TAVR (80%, 
p <0.001). Distribution of DPC was: no/mild 15.2%, moderate 59.6%, severe 25.3%. (Table) Patients with severe DPC were treated more commonly 
via transapical access and had higher rates of major vascular complications and major/life-threatening bleeding. Thirty-day and 1-year death rates 
were significantly higher in the group with severe DPC than in the other groups. However, landmark analysis revealed that in patients surviving 1 
month, those with severe DPC had similar 1-year survival (17.5% vs. 20.8% for no/mild DPC and 13.5% for moderate DPC, p=0.25).
conclusion: In patients undergoing TAVR, severe post procedurals DPC is common and associated with major vascular and bleeding complications, 
resulting in increased mortality.
No/minimal DPC (<25%)
(n=75)
Moderate DPC (≥25 and <50%)
(n=295)
Severe DPC (≥50%)
(n=125)
P
Age (years) 83.6 ± 7.8 85.2 ± 7.2 84.2 ± 7.6 0.17
STS score (%) 11.4 ± 4.3 11.4 ± 4.4 11.7 ± 4.4 0.83
Transapical access 31.1% 24.7% 40.3% 0.006
30-day major vascular complication 3.3% 4.2% 23.7% <0.001
30-day major/life-threatening bleeding 3.3% 3.4% 14.8% 0.02
30-day major stroke 2.6% 2.6% 5.3% 0.11
30-day death 4.0% 2.0% 17.6% <0.001
1-year death 24.0% 15.3% 32.1% <0.001
